<abstract><p>Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000–1,200 mg/day, cutoff body weight of 75 kg) were randomly assigned to receive a total duration of 48 (n = 94) or 24 (n = 93) weeks of therapy. The primary endpoint was sustained virologic response (SVR). Baseline patient characteristics to predict SVR were analyzed. Patients receiving 48 weeks of treatment had a greater SVR rate than those receiving 24 weeks of treatment (70.2% versus 46.2%, <italic>P</italic> = 0.001). Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: −5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction <italic>P</italic> = 0.002). In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naïve HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR.</p></abstract><sec><title>Results</title><sec><title>Patient Characteristics</title><p>Among the 190 patients not achieving RVR by Peg-IFN plus weight-based RBV therapy, 187 were allocated to a total duration of 48-week (n = 94) or 24-week (n = 93) therapy. Seventy-four (78.7%) and 80 (86.0%) patients assigned to 48-week and 24-week therapies completed treatment, and 87 (92.6%) and 88 (94.6%) patients completed 24 weeks of post-treatment follow-up to assess the SVR rates (<xref>Fig. 1</xref>). The baseline patient characteristics were comparable between the two arms (<xref>Table 1</xref>).They were slim with an average BMI of 26.3–26.7 kg/m<sup>2</sup>.Most of the patients had high baseline viral load (62–65%) and favorable IL-28B rs8099917 genotype (71–74%), and were infected with 2a subtype (68–71%). With regard to aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score, 23.7–27.7% patients had a score of &gt;2.00.</p></sec><sec><title>Efficacy</title><p>The early virologic response (EVR) (91.5% versus 88.2%, RD: 3.3% [95% CI: −5.3% to 12.0%]; <italic>P</italic> = 0.45) and the end-of-treatment virologic response (ETVR) (88.3% versus 80.6%, RD: 7.7% [95% CI: −2.7% to 18.0%]; <italic>P</italic> = 0.15) rates were comparable between the treatment arms. The SVR rate of 48-week treatment was greater than 24-week treatment (70.2% versus 46.2%, RD: 24.0% [95% CI: 10.3% to 37.7%]; <italic>P</italic> = 0.001) (<xref>Table 2</xref>). Patients with RBV cumulative exposure &lt;60% had lower SVR rates than those with RBV cumulative exposure ≥60% in 48-week arm (77.6% versus 38.9%, <italic>P </italic>= 0.003) and 24-week arm (53.8% versus 6.7%, <italic>P </italic>= 0.001), respectively.</p></sec><sec><title>Subgroup Analyses for Prespecified Factors</title><p>Differences of SVR rates between patients receiving 48 and 24 weeks of treatment did not vary by baseline viral load (interaction <italic>P</italic> = 0.82), subgenotype (interaction <italic>P</italic> = 0.89), age (interaction <italic>P</italic> = 0.73), sex (interaction <italic>P</italic> = 0.94), body mass index (BMI) (interaction <italic>P</italic> = 0.26), APRI score (interaction <italic>P</italic> = 0.83) or RBV cumulative exposure (interaction <italic>P </italic>= 0.48) (<xref>Table 3</xref>). Compared to patients with favorable IL-28B rs8099917 genotype (69.2% versus 58.3%, risk difference (RD): 10.9% [95% CI: −5.9% to 27.7%]), patients with unfavorable IL-28B rs8099917 genotypes receiving 48-week therapy achieved a greater SVR rate than 24-week therapy (73.9% versus 8.3%, RD: 65.6% [95% CI: 44.5% to 86.7%]; interaction <italic>P</italic> = 0.002). The SVR rates of 48-week and 24-week treatment were similar when the patients had BMI &gt;30 kg/m<sup>2</sup> (52.6% versus 50.0%, RD: 2.6% [95% CI: −33.5% to 38.8%]).</p></sec><sec><title>Safety</title><p>The constitutional and laboratory adverse events (AEs) were similar between the two arms (<xref>Table 4</xref>). Four and 3 patients in 48-week and 24-week arms had serious AEs during treatment (4.3% versus 3.2%, RD: 1.1% [95% CI: −4.4% to 6.5%]. The AE-related withdrawal rates were 11.7% in 48-week treatment arm and 6.5% in 24-week treatment arm (RD: 5.2% [95% CI: 2.9% to 13.5%]). The rates of anemia beyond week 6 of treatment were 44.7% and 34.4% (RD: 10.3% [95% CI: −3.7% to 24.2%].</p></sec></sec><fig><label>Figure 1</label><caption><title>Study Flow Diagram. Peg-IFN: peginterferon, RBV: ribavirin; RVR: rapid virologic response, AE: adverse event.</title></caption><graphic></graphic></fig><fig><label>Figure 2</label><caption><title>Study Design. Peg-IFN: peginterferon, RBV: ribavirin; RVR: rapid virologic response, ETV: early virologic response, ETVR: end-of-treatment virologic response, SVR: sustained virologic response, SD: weight-based dosing, W: week.</title></caption><graphic></graphic></fig><table-wrap><label>Table 1</label><caption><title>Baseline Patient Characteristics<xref>*</xref>.</title></caption><table><colgroup><col/><col/><col/></colgroup><thead><tr><th>Characteristics</th><th>SD48W, N = 94</th><th>SD24W, N = 93</th></tr></thead><tbody><tr><td>Mean age (SD), y</td><td>56 (12)</td><td>56 (13)</td></tr><tr><td>Age &gt;50 y</td><td>64 (68)</td><td>59 (63)</td></tr><tr><td>Male sex</td><td>51 (54)</td><td>52 (56)</td></tr><tr><td>Mean weight (SD), kg</td><td>69 (13)</td><td>69 (11)</td></tr><tr><td>Mean BMI (SD), kg/m<sup>2</sup></td><td>26.7 (4.5)</td><td>26.3 (3.5)</td></tr><tr><td>BMI (SD), kg/m<sup>2</sup></td></tr><tr><td> ≤27.0</td><td>54 (57.4)</td><td>52 (55.9)</td></tr><tr><td> 27.1–30.0</td><td>21 (22.3)</td><td>29 (31.2)</td></tr><tr><td> &gt;30.0</td><td>19 (20.2)</td><td>12 (12.9)</td></tr><tr><td>Mean hemoglobin level (SD), g/dL</td><td>14.4 (1.5)</td><td>14.7 (1.4)</td></tr><tr><td>Mean white cell count (SD), 10<sup>9</sup>cells/L</td><td>5.6 (1.4)</td><td>5.8 (1.5)</td></tr><tr><td>Mean neutrophil count (SD), 10<sup>9</sup>cells/L</td><td>3.0 (1.1)</td><td>3.2 (1.2)</td></tr><tr><td>Mean platelet count (SD), 10<sup>9</sup>cells/L</td><td>175 (61)</td><td>182 (64)</td></tr><tr><td>Mean albumin level (SD), g/dL</td><td>4.3 (0.4)</td><td>4.3 (0.3)</td></tr><tr><td>Mean total bilirubin level (SD), mg/dL</td><td>1.0 (0.4)</td><td>1.0 (0.5)</td></tr><tr><td>Mean AST quotient (SD), ULN</td><td>2.2 (1.2)</td><td>2.3 (1.1)</td></tr><tr><td>Mean ALT quotient (SD), ULN</td><td>3.4 (2.1)</td><td>3.8 (2.3)</td></tr><tr><td>Mean APRI score (SD)</td><td>1.5 (1.0)</td><td>1.5 (1.1)</td></tr><tr><td>APRI score</td></tr><tr><td> ≤1.50</td><td>56 (59.6)</td><td>50 (53.8)</td></tr><tr><td> 1.51–2.0</td><td>12 (12.7)</td><td>21 (22.5)</td></tr><tr><td> &gt;2.00</td><td>26 (27.7)</td><td>22 (23.7)</td></tr><tr><td>Mean HCV RNA level (SD), log<sub>10</sub> IU/mL</td><td>6.0 (0.9)</td><td>6.0 (0.6)</td></tr><tr><td>HCV RNA level, IU/mL</td></tr><tr><td> ≤800,000</td><td>33 (35)</td><td>35 (38)</td></tr><tr><td> &gt;800,000</td><td>61 (65)</td><td>58 (62)</td></tr><tr><td>Subgenotype</td></tr><tr><td> 2a</td><td>64 (68)</td><td>66 (71)</td></tr><tr><td> 2b</td><td>24 (26)</td><td>20 (22)</td></tr><tr><td> 2a + 2b</td><td>6 (6)</td><td>7 (8)</td></tr><tr><td>IL-28B rs8099917 genotype<xref>†</xref></td></tr><tr><td> TT</td><td>65 (74)</td><td>60 (71)</td></tr><tr><td> GT and GG</td><td>23 (26)</td><td>24 (29)</td></tr></tbody></table><table-wrap-foot><fn><p>SD: standard deviation, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ULN: upper limit of normal, APRI: aspartate aminotransferase to platelet ratio index, HCV: hepatitis C virus, IU: international unit, IL: interleukin, SD48W: 48 weeks of peginterferon alfa-2a plus weight-based ribavirin, SD24W: 24 weeks of peginterferon alfa-2a plus weight-based ribavirin.</p></fn><fn><p><sup>*</sup>Values are numbers (percentages) unless otherwise indicated.</p></fn><fn><p><sup>†</sup>Available number of patients (%) for analysis: 88 (94%) and 84 (90%) in SD48W and SD24W arms, respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap><label>Table 2</label><caption><title>On-treatment and Off-treatment Virologic Responses.</title></caption><table><colgroup><col/><col/><col/><col/><col/></colgroup><thead><tr><th>Variable</th><th>SD48W, n/N (%)</th><th>SD24W, n/N (%)</th><th>RD (95% CI)</th><th><italic>P</italic> value<xref>*</xref></th></tr></thead><tbody><tr><td>On-treatment virologic response</td></tr><tr><td> EVR</td><td>86/94 (91.5)</td><td>82/93 (88.2)</td><td>3.3 (−5.3 to 12.0)</td><td>0.45</td></tr><tr><td> ETVR</td><td>83/94 (88.3)</td><td>75/93 (80.6)</td><td>7.7 (−2.7 to 18.0)</td><td>0.15</td></tr><tr><td>Virologic outcome</td></tr><tr><td> SVR<xref>†</xref></td><td>66/94 (70.2)</td><td>43/93 (46.2)</td><td>24.0 (10.3 to 37.7)</td><td>0.001</td></tr><tr><td> Non-SVR</td><td>28/94 (29.8)</td><td>50/93 (53.8)</td><td> </td><td> </td></tr><tr><td> Relapse</td><td>12/94 (12.8)</td><td>28/93 (30.1)</td><td> </td><td> </td></tr><tr><td> Null-response<xref>‡</xref></td><td>9/94 (9.6)</td><td>12/93 (12.9)</td><td> </td><td> </td></tr><tr><td> Viral breakthrough<xref>§</xref></td><td>2/94 (2.1)</td><td>5/93 (5.4)</td><td> </td><td> </td></tr><tr><td> Undetermined<xref>||</xref></td><td>5/94 (5.3)</td><td>5/93 (5.4)</td><td> </td><td> </td></tr></tbody></table><table-wrap-foot><fn><p>RD; risk reduction, EVR: early virologic response, ETVR: end-of-treatment virologic response, SVR: sustained virologic response, CI: confidence interval.</p></fn><fn><p><sup>*</sup>P values were obtained by Wald asymptotic test.</p></fn><fn><p><sup>†</sup>Patients who were lost to 24-week follow-up, were null-responsive to treatment, or had viral breakthrough or relapsed after treatment were considered failure to achieve SVR.</p></fn><fn><p><sup>‡</sup>SD48W arm: 5 patients failed to achieve EVR; 4 patients achieved EVR but remained viremic at week 24 of treatment. SD24W arm: 7 patients failed to achieve ETR; 5 patients achieved EVR but remained viremic at week 24 of treatment.</p></fn><fn><p><sup>§</sup>SD48W arm: 2 patients had viral breakthrough at week 48 of treatment. SD24W arm: 5 patients had viral breakthrough at week 24 of treatment.</p></fn><fn><p><sup>||</sup>All patients lost to 24-week post-treatment follow-up, and all had undetectable HCV RNA level at the time of treatment discontinuation. SD48W arm: 3 completed 48 weeks of treatment, and 2 prematurely discontinued treatment at weeks 36 and 40 due to serious adverse events. SD24W arm: 2 completed 24 weeks of treatment, 2 prematurely discontinued treatment at weeks 12 and 16 due to serious adverse events and 1 prematurely discontinued treatment at week 12 due to constitutional adverse event.</p></fn></table-wrap-foot></table-wrap><table-wrap><label>Table 3</label><caption><title>Subgroup Analyses of Prespecified Factors for SVR.</title></caption><table><colgroup><col/><col/><col/><col/><col/></colgroup><thead><tr><th>Variable</th><th>SD48W, n/N (%)</th><th>SD24W, n/N (%)</th><th>RD (95% CI)</th><th><italic>P</italic>value for interaction<xref>*</xref></th></tr></thead><tbody><tr><td>Baseline viral load</td><td> </td><td> </td><td> </td><td>0.82</td></tr><tr><td> ≤800,000 IU/mL</td><td>27/33 (81.8)</td><td>21/35 (60.0)</td><td>21.8 (0.9 to 42.7)</td><td> </td></tr><tr><td> &gt;800,000 IU/mL</td><td>39/61 (63.9)</td><td>22/58 (37.9)</td><td>26.0 (8.7 to 43.3)</td><td> </td></tr><tr><td>Subgenotype</td><td> </td><td> </td><td> </td><td>0.89</td></tr><tr><td> 2a</td><td>44/64 (68.8)</td><td>31/66 (45.5)</td><td>21.8 (5.2 to 38.3)</td><td> </td></tr><tr><td> 2b</td><td>18/24 (75.0)</td><td>10/20 (50.0)</td><td>25.0 (−2.9 to 52.9)</td><td> </td></tr><tr><td> 2a+2b</td><td>4/6 (67.7)</td><td>3/7 (42.9)</td><td>23.8 (−28.8 to 76.4)</td><td> </td></tr><tr><td>IL-28B rs8099917 genotype<xref>†</xref></td><td> </td><td> </td><td> </td><td>0.002</td></tr><tr><td> TT</td><td>45/65 (69.2)</td><td>35/60 (58.3)</td><td>10.9 (−5.9 to 27.7)</td><td> </td></tr><tr><td> GT and GG</td><td>17/23 (73.9)</td><td>2/24 (8.3)</td><td>65.6 (44.5 to 86.7)</td><td> </td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td>0.73</td></tr><tr><td> ≤50 y</td><td>23/30 (76.7)</td><td>17/34 (50.0)</td><td>26.7 (4.1 to 49.3)</td><td> </td></tr><tr><td> &gt;50 y</td><td>43/64 (67.2)</td><td>26/59 (44.1)</td><td>23.1 (6.1 to 40.2)</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td>0.94</td></tr><tr><td> Female</td><td>30/43 (69.8)</td><td>19/41 (46.3)</td><td>23.4 (2.9 to 44.0)</td><td> </td></tr><tr><td> Male</td><td>36/51 (70.6)</td><td>24/52 (46.2)</td><td>24.4 (6.0 to 43.0)</td><td> </td></tr><tr><td>BMI</td><td> </td><td> </td><td> </td><td>0.26</td></tr><tr><td> ≤27.0 kg/m<sup>2</sup></td><td>41/54 (75.9)</td><td>25/52 (48.1)</td><td>27.9 (10.1 to 45.6)</td><td> </td></tr><tr><td> 27.1–30.0 kg/m<sup>2</sup></td><td>15/21 (71.4)</td><td>12/29 (41.4)</td><td>30.1 (3.7 to 56.4)</td><td> </td></tr><tr><td> &gt;30.0 kg/m<sup>2</sup></td><td>10/19 (52.6)</td><td>6/12 (50.0)</td><td>2.6 (−33.5 to 38.8)</td><td> </td></tr><tr><td>APRI score</td><td> </td><td> </td><td> </td><td>0.83</td></tr><tr><td> ≤1.50</td><td>38/56 (67.9)</td><td>23/50 (46.0)</td><td>21.9 (3.4 to 40.3)</td><td> </td></tr><tr><td> 1.51–2.00</td><td>9/12 (75.0)</td><td>9/21 (42.9)</td><td>32.1 (−0.2 to 64.5)</td><td> </td></tr><tr><td> &gt;2.00</td><td>19/26 (73.1)</td><td>11/22 (50.0)</td><td>23.1 (−3.9 to 50.0)</td><td> </td></tr><tr><td>RBV cumulative exposure</td><td> </td><td> </td><td> </td><td>0.48</td></tr><tr><td> &lt;60%</td><td>7/18 (38.9)</td><td>1/15 (6.7)</td><td>32.2 (6.4 to 58.4)</td><td> </td></tr><tr><td> 60%–80%</td><td>15/19 (77.8)</td><td>9/20 (45.0)</td><td>34.0 (5.5 to 62.4)</td><td> </td></tr><tr><td> ≥80%</td><td>44/57 (77.2)</td><td>33/58 (56.9)</td><td>20.3 (3.5 to 37.1)</td><td> </td></tr></tbody></table><table-wrap-foot><fn><p>RD: risk reduction, CI: confidence interval, IL: interleukin, BMI: body mass index, APRI: aspartate aminotransferase to platelet ratio index</p></fn><fn><p><sup>*</sup>The interaction for the prespecified factors was compared by stratified Mantel-Haenszel test.</p></fn><fn><p><sup>†</sup>Available number of patients (%) for analysis: 88 (94%) and 84 (90%) in SD48W and SD24W arms, respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap><label>Table 4</label><caption><title>Adverse Events, Dose reduction and Treatment Discontinuation in Treated Patients <xref>*</xref>.</title></caption><table><colgroup><col/><col/><col/></colgroup><thead><tr><th>Parameter</th><th>SD48W, N = 94</th><th>SD24W, N = 93</th></tr></thead><tbody><tr><td>Serious AEs</td></tr><tr><td>All<xref>†</xref></td><td>4 (4.3)</td><td>3 (3.2)</td></tr><tr><td>Death</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>Treatment-related</td><td>3 (3.2)</td><td>3 (3.2)</td></tr><tr><td>Treatment withdrawal due to AEs</td><td>11 (11.7)</td><td>6 (6.5)</td></tr><tr><td>Dose reduction to AEs</td></tr><tr><td>Peginterferon</td><td>23 (24.5)</td><td>20 (21.5)</td></tr><tr><td>Ribavirin</td><td>45 (47.9)</td><td>35 (37.6)</td></tr><tr><td>Constitutional AEs</td></tr><tr><td>Flu-like symptoms</td><td>29 (30.9)</td><td>27 (29.0)</td></tr><tr><td>Fatigue</td><td>57 (60.6)</td><td>54 (58.1)</td></tr><tr><td>Headache</td><td>26 (27.7)</td><td>28 (30.1)</td></tr><tr><td>Insomnia</td><td>34 (36.2)</td><td>33 (35.5)</td></tr><tr><td>Irritability</td><td>11 (11.7)</td><td>10 (10.8)</td></tr><tr><td>Depression</td><td>14 (14.9)</td><td>12 (12.9)</td></tr><tr><td>Anorexia</td><td>30 (31.9)</td><td>27 (29.0)</td></tr><tr><td>Diarrhea</td><td>12 (12.8)</td><td>12 (12.9)</td></tr><tr><td>Constipation</td><td>11 (11.7)</td><td>8 (8.6)</td></tr><tr><td>Cough</td><td>14 (14.9)</td><td>15 (16.1)</td></tr><tr><td>Dermatitis</td><td>28 (29.8)</td><td>25 (26.9)</td></tr><tr><td>Injection site reaction</td><td>15 (16.0)</td><td>13 (14.0)</td></tr><tr><td>Hair loss/alopecia</td><td>25 (26.6)</td><td>24 (25.8)</td></tr><tr><td>Laboratory AEs<xref>‡</xref></td></tr><tr><td>Anemia (week 1–6)<xref>§</xref></td><td>7 (7.4)</td><td>6 (6.5)</td></tr><tr><td>Hemoglobin level: 8.5–9.9 g/dL</td><td>6 (6.4)</td><td>5 (5.4)</td></tr><tr><td>Hemoglobin level: &lt;8.5 g/dL</td><td>1 (1.1)</td><td>1 (1.1)</td></tr><tr><td>Anemia (week 6 to end-of-treatment)<xref>§</xref></td><td>42 (44.7)</td><td>32 (34.4)</td></tr><tr><td>Hemoglobin level: 8.5–9.9 g/dL</td><td>27 (28.7)</td><td>22 (23.7)</td></tr><tr><td>Hemoglobin level: &lt;8.5 g/dL</td><td>15 (16.0)</td><td>10 (10.8)</td></tr><tr><td>Neutropenia</td><td>17 (18.1)</td><td>14 (15.1)</td></tr><tr><td>Neutrophil count: 0.500–0.749 × 10<sup>9</sup> cells/L</td><td>13 (13.8)</td><td>11 (11.8)</td></tr><tr><td>Neutrophil count: &lt;0.500 × 10<sup>9</sup> cells/L</td><td>4 (4.3)</td><td>3 (3.2)</td></tr><tr><td>Thrombocytopenia</td><td>9 (9.6)</td><td>11 (11.8)</td></tr><tr><td>Platelet count: 25–49 × 10<sup>9</sup> cells/L</td><td>8 (8.5)</td><td>10 (10.8)</td></tr><tr><td>Platelet count: &lt;25 × 10<sup>9</sup> cells/L</td><td>1 (1.1)</td><td>1 (1.1)</td></tr><tr><td>ALT elevation</td></tr><tr><td>&gt;2 times ULN</td><td>16 (17.0)</td><td>18 (19.4)</td></tr><tr><td>&gt;5 times ULN</td><td>2 (2.1)</td><td>3 (3.2)</td></tr><tr><td>Total bilirubin elevation<xref>¶</xref></td></tr><tr><td>&gt;2 mg/dL</td><td>5 (5.3)</td><td>4 (4.3)</td></tr><tr><td>&gt;5 mg/dL</td><td>0 (0.0)</td><td>0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn><p>AE: adverse event, ALT: alanine aminotransferase, ULN: upper limit of normal.</p></fn><fn><p><sup>*</sup>Values are numbers (percentages).</p></fn><fn><p><sup>†</sup>SD48W arm: spontaneous bacterial peritonitis at week 36 of treatment, cellulitis at week 20 of treatment, severe anemia with postural dizziness at week 12 of treatment (hemoglobin level: 7.1 g/dL), and multiple myeloma at week 40 of treatment. SD24W arm: urinary tract infection at week 12 of treatment, community-acquired pneumonia at week 16 of treatment, severe anemia with postural dizziness at week 16 of treatment (hemoglobin level: 7.3 g/dL), respectively. All except the patients developing multiple myeloma were considered treatment-related.</p></fn><fn><p><sup>‡</sup>The grading of the laboratory AEs was shown for patients with the on-treatment nadir level.</p></fn><fn><p><sup>§</sup>Anemia was defined as a nadir hemoglobin level &lt;10.0 g/dL.</p></fn><fn><p><sup>¶</sup>No patient with total bilirubin elevation had concomitant ALT elevation &gt;5 times ULN.</p></fn></table-wrap-foot></table-wrap>